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Neonatal screening in Macedonia detects congenital hypothyroidism (CH) with an
incidence of 1 in 1,585, and more than 50% of cases exhibit a normally located
gland-in-situ (GIS). Monogenic mutations causing dyshormonogenesis may underlie
GIS CH; additionally, a small proportion of thyroid hypoplasia has a monogenic cause,
such as TSHR and PAX8 defects. The genetic architecture of Macedonian CH cases
has not previously been studied. We recruited screening-detected, non-syndromic GIS
CH or thyroid hypoplasia cases (n = 40) exhibiting a spectrum of biochemical thyroid
dysfunction ranging from severe permanent to mild transient CH and including 11 familial
cases. Cases were born at term, with birth weight >3,000 g, and thyroid morphologies
included goiter (n = 11), thyroid hypoplasia (n = 6), and apparently normal-sized thyroid.
A comprehensive, phenotype-driven, Sanger sequencing approach was used to identify
genetic mutations underlying CH, by sequentially screening known dyshormonogenesis-
associated genes and TSHR in GIS cases and TSHR and PAX8 in cases with thyroid
hypoplasia. Potentially pathogenic variants were identified in 14 cases, of which four
were definitively causative; we also detected digenic variants in three cases. Seventeen
variants (nine novel) were identified in TPO (n= 4), TG (n= 3), TSHR (n= 4), DUOX2 (n=
4), and PAX8 (n = 2). No mutations were detected in DUOXA2, NIS, IYD, and SLC26A7.
The relatively low mutation frequency suggests that factors other than recognized
monogenic causes (oligogenic variants, environmental factors, or novel genes) may
contribute to GIS CH in this region. Future non–hypothesis-driven, next-generation
sequencing studies are required to confirm these findings.
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INTRODUCTION
Congenital hypothyroidism (CH) is traditionally divided into dysgenesis (abnormal thyroid
development) and dyshormonogenesis, where thyroid hormone biosynthesis is inadequate
despite a structurally normal or goitrous thyroid. Shortly after the implementation of CH
neonatal screening, studies investigating the incidence of CH generally reported an incidence
of approximately 1:3,000, of which the majority was due to thyroid dysgenesis, with only 20%
occurring due to dyshormonogenesis. More recent studies have reported a doubling in the
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incidence of CH, largely due to increased diagnosis of cases with
a normally located gland-in-situ (GIS CH). Thyroid dysgenesis
usually occurs because of an ectopic thyroid or athyreosis,
and thyroid hypoplasia remains the least common thyroid
developmental abnormality (1–3).
The etiology of GIS CH is generally unclear; however, some
cases may harbor mutations in genes involved in thyroid
hormone biosynthesis or development. Dyshormonogenic CH
may occur because of biallelic mutations in anion transporters
mediating thyroidal iodide uptake or efflux (SLC5A5/NIS or
SLC26A4/pendrin, respectively); SLC26A7; TPO (the thyroid
peroxidase enzyme), which catalyzes organification of iodide and
the formation of thyroid hormones; and thyroglobulin (TG),
upon which thyroid hormone biosynthesis and storage occur.
Additional causes include monoallelic and biallelic mutations
in the NADPH-oxidase DUOX2, which generates thyroidal
hydrogen peroxide; its accessory protein DUOXA2; and IYD,
which recycles unused iodide (1, 4, 5). Mutations in TSHR, the
G-protein–coupled receptor for thyroid-stimulating hormone
(TSH) cause a spectrum of phenotypes ranging from severe
thyroid hypoplasia to a normal-sized GIS, with the severity
correlating with the number of mutated TSHR alleles and the
degree of receptor functional impairment (6). Thyroid dysgenesis
infrequently has a monogenic basis. Isolated thyroid hypoplasia
may occur because of PAX8 or TSHR mutations, and mutations
in the transcription factors NKX2-1 and FOXE1 cause CH in
association with more extensive developmental syndromes (1).
The Republic of North Macedonia is a multiethnic country
comprising a majority of Macedonians of Slavic origin at 64.2,
25.2% ethnic Albanians, 2.7% Roma, 3.9% Turks, and 2.2%
of other ethnicities (7). Neonatal screening for CH has been
mandatory in Macedonia since 2007, following a 5-year pilot
study from 2002 to 2006, which included only the largest birth
centers in the country. A single screening center within the
University Children’s Hospital in Skopje conducts the national
screening program, accepting approximately 24,000 neonatal
samples annually. A total of 295,909 newborns were screened
between 2002 and 2017 with a mean coverage of 97.03%.
Whole-blood TSH was measured from filter paper blood spots
(Whatman 903), sampled 48 to 72 h after birth. The TSH
cutoff level was 15 mU/L in the period 2002–2010, and 10
mU/L thereafter, which resulted in an increased prevalence
of primary CH in Macedonia, from 1/2,489 live births before
2010 to 1/1,585 from 2011 onward (an increment of 36.3%)
(8). A total of 153 patients were diagnosed with primary
CH over this 15-year period (8–10). At reevaluation, 48.4%
had permanent hypothyroidism, 30% transient CH, and 21.6%
isolated hyperthyrotropinemia. Almost all cases with isolated
hyperthyrotropinemia or transient CH had a normally located
GIS except for two cases with isolated hyperthyrotropinemia and
gland hypoplasia. Fourteen percent of permanent CH cases had
likely dyshormonogenesis, and 86% had thyroid dysgenesis, of
which athyreosis was the most prevalent form (53%), followed by
thyroid ectopia (30%), and thyroid hypoplasia (17% of thyroid
dysgenesis cases).
No studies have yet been performed to investigate the genetic
basis of CH inMacedonia, despite the high percentage of GIS CH
cases with potential genetically mediated dyshormonogenesis.
Here, we investigated cases with non-syndromic GIS CH
and normal-sized, goitrous or hypoplastic thyroid glands,
either diagnosed over the aforementioned period or recruited
prospectively. We used a comprehensive, sequential, targeted
Sanger sequencing approach, aiming to delineate the role
of mutations in known dyshormonogenesis-associated
genes, TSHR and PAX8, in CH cases in this multiethnic
Macedonian population.
MATERIALS AND METHODS
Cohort Selection
The study was approved by Cambridge South REC (MREC
98/5/24) and the ethical committee atMedical Faculty, University
Ss Cyril and Methodius in Skopje, and includes additional
measurements undertaken as part of routine clinical follow-up
with written, informed consent from patients and/or next of kin.
Congenital hypothyroidism cases born at term (n = 40)
were selected for investigation if specific genetic causes of
CH were suspected because of (1) scintigraphic features of
dyshormonogenesis, (2) goiter, (3) familial occurrence of CH, (4)
thyroid hypoplasia, and/or (5) cases with unexplained transient
CH or isolated hyperthyrotropinemia. We did not recruit cases
with athyreosis or ectopy because these individuals were deemed
less likely to have an identifiable genetic cause, and labor and
cost considerations precluded expansion of case numbers or
inclusion of additional genes in our Sanger sequencing–based
study. Screening-detected primary CH required TSH >10 mU/L
and low or normal total T4 (T4) or free T4 (FT4) on confirmatory
serum measurements. All children with GIS CH aged ≥3 years
underwent a trial of treatment withdrawal for 4 weeks and were
classified as follows: permanent CH (TSH>10 mU/L, subnormal
total or FT4), transient CH (normal thyroid tests after the trial
off therapy and at least 6 months’ follow-up period), and isolated
hyperthyrotropinemia (TSH values between 5 and 10 mU/L with
normal total or FT4). We recruited cases seen in our clinics over
a 1-year period and studied 34 cases with a normally located
or hypoplastic GIS out of a total of 100 eligible cases from
the original cohort, as well as six additional patients recruited
prospectively, who did not undergo a trial off levothyroxine.
Many of the original 153 cases were no longer under pediatric
care or had been lost to follow-up because of emigration, and a
small minority did not consent to participate.
Prioritization of Genes for Sanger
Sequencing
Genes were screened sequentially by Sanger sequencing following
the strategy outlined in Figure 1 and summarized below, using
phenotypic data (CH outcome and thyroid morphology) to
predict the genes most likely to harbor mutations in the
individual cases. Once a robust, likely causative variant was
found, no further genes were sequenced. In cases where there
was more than one affected family member, only one affected
individual was sequenced, and the affected relative was genotyped
if a likely causative variant was identified. Familial cases included
eight siblings (four pairs) and two affected cousins (one pair)
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FIGURE 1 | Strategy by which Sanger sequencing was used to screen individual genes most likely to be implicated in the pathogenesis of CH in particular phenotypic
subgroups. Genes in gray boxes denote the genes sequenced in each subgroup. SLC5A5 (NIS) was sequenced only in cases lacking pertechnetate scan data;
otherwise, normal isotope uptake was assumed to indicate preserved NIS function. TSH values represent the median and (minimum-maximum) range; cases with
TSH >75 mU/L were said to have TSH 75 mU/L for the purposes of these calculations. Cases harboring possible pathogenic genetic variants are listed for each CH
category. All mutations were heterozygous or compound heterozygous. IH, isolated hyperthyrotropinemia; GIS, normal-sized, normally located gland-in-situ. Case 79
was presumed to have permanent CH based on levothyroxine dose requirements and the presence of goiter. Cases in whom CH was not reevaluated refer to those in
whom a trial of levothyroxine withdrawal was not undertaken.
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with likely autosomal recessive inheritance and an additional case
with an affected father in whomwe hypothesized that inheritance
would be autosomal dominant.
Normal-sized GIS/goiter (n = 23) with either permanent
CH (n = 9), idiopathic hyperthyrotropinemia (n = 9), or CH
that was not reevaluated (n = 5): TG, TPO, DUOX2, DUOXA2,
IYD, and SLC26A7 were screened, in addition to SLC5A5 (NIS) in
cases lacking pertechnetate scan data. Otherwise normal isotope
uptake was assumed to indicate preserved NIS function. TSHR
and PAX8 were also screened in cases with a normal-sized GIS (n
= 14) but not in goitrous cases (n= 9).
Transient CH (n = 11)
Cases with normal-sized GIS (n = 9): TSHR, DUOX2, and
DUOXA2 were screened. Cases with goiter (n = 2): DUOX2
and DUOXA2 were screened. In cases for whom pertechnetate
scan data were lacking, SLC5A5 (NIS) was also screened, unless
uptake was normal in a sibling (one sibling pair) or there was
insufficient DNA (n= 1 case).
Cases with thyroid hypoplasia (n = 6) with either
permanent CH (n = 3), idiopathic hyperthyrotropinemia
(n = 2), or CH that was not reevaluated (n = 1): TSHR
and PAX8 were screened irrespective of TSH level and CH
outcome, because mutations in these genes are well-recognized
causes of isolated thyroid hypoplasia, and the six cases all had
CH without extrathyroidal manifestations. SLC26A4 was not
sequenced, because none of our cohort exhibited sensorineural
deafness suggesting Pendred syndrome.
Sanger Sequencing
Genomic DNA was extracted from peripheral blood leukocytes
using standard techniques. All coding exons and exon/intron
boundaries for the genes of interest were amplified by polymerase
chain reaction using specific primers (available on request).
Wherever possible, family members were also genotyped
for mutations identified in the CH cases. Polymerase chain
reaction products were sequenced using the BigDye Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City,
CA, USA) and 3730 DNA Analyzer (Applied Biosystems).
Variants were described using the systematic nomenclature
approved by the Human Genome Variation Society (www.
hgvs.org/mutnomen). Nucleotide numbering starts from A
(+1) of the translation initiation codon (ATG) of the NCBI
reference sequences below and includes the signal peptide
where present: NM_001206744, NP_001193673 (TPO),
NM_003235, NP_003226 (TG), NM_014080, NP_054799
(DUOX2), NM_207581, NP_997464 (DUOXA2), NM_000453,
NP_000444 (SLC5A5), NM_203395, NP_981932 (IYD) and
NM_000369, NP_000360 (TSHR), NM_003466.4, NP_003457.1
(PAX8), NM_052832.4, NP_439897.1 (SLC26A7).
Variant Analysis
Variants with global minor allele frequency (MAF) <0.01
and maximal minor allele frequency <0.02 in the ExAC
database (http://exac.broadinstitute.org) were assessed using the
in silico pathogenicity prediction tools PolyPhen-2, SIFT, and
MutationTaster. SIFT and PolyPhen-2 scores were calculated
using Ensembl Variant Effect Predictor where possible or
PROVEAN (for SIFT) (11–14). This relatively high maximal
MAF cutoff was selected because it is recognized that certain
mutations, especially those in DUOX2, may occur with relatively
high population frequencies (MAF ≥0.01) in individuals of
particular ethnicities, for example, DUOX2 p.F966Sfs∗29 (15).
Novel mutations were defined as those not present in HGMD
Professional (HGMD R© (http://www.hgmd.cf.ac.uk) and not
detected during an NCBI PubMed search for genetic studies in
CH (16).
We used three in silico pathogenicity predictors to assess
whether variants with maximal MAF < 0.02 were likely to
be pathogenic and classified them according to the American
College of Medical Genetics Guidelines. Variants were only
considered to be possible contributors to CH if they were
predicted damaging by one or more predictors, that is, predicted
to be at least “possibly damaging” or “probably damaging”
with PolyPhen-2 or “damaging” with SIFT or “disease causing”
with MutationTaster. Given that no functional studies were
undertaken in our study, and recognizing the limitations of in
silico analysis, we also performed a literature search for known
mutations in order to inform further classification of the variants.
We classified causative variants as those for which the
inheritance pattern in the patient was consistent with causality
and for which there was robust evidence from the literature
supporting pathogenicity or where the mutations resulted in
a truncated protein. Variants of uncertain significance were
deemed to be possibly contributing to CH if we could not be
confident that they were benign on the basis of these analyses.
These data are presented inTable 1 but discussed in greater detail
in the Results and Discussion.
Urinary Iodine Measurement
Twenty-four-hour urinary iodide excretion was measured at the
National Laboratory for Determining Iodine in Urine using
method A [World Health Organization (WHO)/United Nations
International Children’s Fund (UNICEF)/International Council
for the Control of Iodine Deficiency Disorders (ICCIDD)]
with ammonium persulfate solution and spectrophotometric
detection of the Sandell–Kolthoff reaction (Spectrophotometer
UNICO UV-2102, USA). The results of urine iodide excretion
were interpreted in accordance with WHO recommendations
(school-aged children: adequate iodide: 100–199 µg/L, iodide
excess >300 µg/L; children aged <2 years: adequate iodide≥100
µg/L, insufficient iodide ≤100 µg/L).
Thyroid Imaging
Thyroid pertechnetate scans were performed at diagnosis using
a double-head Mediso gamma camera after an intravenous
injection of 99 m-technetium pertechnetate (2 MBq/kg),
obtaining standard anterior and lateral images and recording
the size and location of areas of 99m TcO4 uptake. Thyroid
ultrasound (SonoScape SSI-5000 Color Doppler Ultrasound
System; SonoScape Medical Corp., Shenzhen, China) was
performed by a single experienced physician at diagnosis,
comparing the volume of the thyroid lobes with reference values
from the literature.
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TABLE 1 | Genetic variants in mutation-positive cases.
Case
ID no.
TSH
(mU/L)
Anti-TPO
negative:
<10
IU/mL
CH
outcome,
thyroid
size
Gene cDNA
variant
Protein
variant
Zyg Max
MAF
(ExAC)
PP2 SIFT MT ACMG
Cases with likely causative variants
44 14.1 ND Tr, GIS DUOX2 c.4637A>G p.E1546G Het 0.0014 PD D DC LP
49 50 Negative IH, GIS *TSHR c.1516G>A p.E506K (M) Het 1.5 ×
10−5
PD D DC VUS
DUOX2 *c.280G>A p.G94S (M) Compoundhet — PD D DC VUS
c.2895_2898
delGTTC
p.F966Sfs*29
(F)
0.012 PD D DC P
74 16.5 Negative IH, GIS *PAX8 c.724delC p.R242Gfs*37
(M)
Het — NA NA DC P
79 159 ND Presumed
Per, Goiter
TPO c.31_50dup20 p.E17Dfs*77
(F)
Compound
het
3 × 10−5 NA NA DC P
c.1313G>A p.R438H (M) — PD D DC LP
Cases with possible contributory variants
27 >75 Negative Per,
Goiter
TPO c.1184_1187
dupGCCG
p.A397Pfs*76
(F)
Het — NA NA DC P
28 >75 Negative Per,
Goiter
TPO c.1184_1187
dupGCCG
p.A397Pfs*76
(F)
Het — NA NA DC P
33 13.8 Negative IH, GIS *TSHR c.692 +
1_692 +
4delGTGA
(splice donor)
NA (M) Het — NA NA DC VUS
TG c.886C>T p.R296* (M) Het 0.0008 NA NA DC P
51 57.7 Negative IH, GIS *TG c.4093A>T p.N1365Y Het 0.0002 PD D DC VUS
71 14.1 ND IH, GIS *TG c.5372delT p.L1791Cfs*12
(F)
Het — NA NA DC P
*TPO c.2395G>C p.E799Q (M) Het — PD D DC VUS
90 13.8 ND NR, GIS *TSHR c.321A>C p.E107D (M) Het — PD T DC VUS
93 30.3 ND IH, GIS PAX8 c.404A>G p.K135R Het 0.008 PD T DC VUS
94 22 ND IH, GIS PAX8 c.404A>G p.K135R Het 0.008 PD T DC VUS
97 66.3 Negative NR, GIS *TSHR c.1355T>C p.L452P (F) Het 1.5 ×
10−5
PD D DC VUS
99 21 Negative NR, Goiter *DUOX2 c.4318G>A p.D1440N (M) Het 3.0 ×
10−5
PD D DC VUS
Zyg, zygosity; max. MAF, maximal minor allele frequency in the ExAC database (European non-Finnish population in all cases); TSH, venous TSH at diagnosis; (M) maternally inherited;
(F) paternally inherited; B, benign; PD, probably damaging; DC, disease causing; T, tolerated; P, pathogenic; LP, likely pathogenic; VUS, variant of uncertain significance; bold, siblings;
ACMG, American College of Medical Genetics classification; MT, MutationTaster; PP-2, PolyPhen-2. *novel variant; Tr, Transient CH; IH, Isolated hyperthyrotropinemia; Per, Permanent
CH; NR, CH not reevaluated for permanency; ND, not done; GIS, normal-sized; normally located gland-in-situ. Gray: variants in oligogenic cases that are possibly contributing to CH,
in addition to variants which are more likely to be causative.
Statistical Analysis
Statistical analyses were performed using Prism (GraphPad
Software Inc., USA), version 5.0 d.
Biochemical Assays
Serum TSH and T4/FT4 and anti–thyroid peroxidase
autoantibodies (anti-TPO) were measured locally using the
IMMULITE 2000 chemiluminescent enzyme immunoassay
system (Siemens Healthcare Diagnostics Inc., USA). Thyroid
hormone levels falling within the 3rd to the 97th percentile
standardized for age were considered normal. The reference
ranges for anti-TPO antibodies were 10–35 IU/mL.
RESULTS
Description of Cohort
Figure 1 summarizes the genetic evaluation undertaken, in
addition tomedian TSH results and imaging data for the 40 cases.
Overall, median serum TSH at diagnosis was 30.3 mU/L (range,
13.7–159 mU/L); the thyroid gland was ultrasonographically
normal sized in 57.5% of cases, goitrous in 27.5%, and hypoplastic
in 15% of cases. The outcome of the CH was determined in 85%
of cases, and equal proportions demonstrated permanent and
transient hypothyroidism and isolated hyperthyrotropinemia.
Eleven cases (27.5%) had familial CH with at least one affected
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relative. In three cases, total T4 was elevated at diagnosis, but
FT4 was normal with elevated TSH, supporting a diagnosis of CH
with a possible binding protein abnormality.
Mutation Positive Cases
Fourteen patients harbored rare genetic variants (Table 1), which
had either been associated with CH in previous studies or which
were novel but predicted to be pathogenic by at least one in silico
predictive tool (PolyPhen-2, SIFT, or MutationTaster). Cases
were subclassified according to the variants found, with only four
cases felt to harbor definitive, causative variants. Ten patients
harbored variants that were possibly contributing to CH, but
either there was insufficient evidence to label the variants as
causative, or the zygosity of the variants did not support sole
causality (e.g., heterozygous TPO or TG mutations). Two of
these cases harbored digenic variants. Mutation-positive cases
harbored variants inTPO,TG,TSHR,DUOX2, and PAX8.Wedid
not detect any mutations in DUOXA2, NIS, IYD, or SLC26A7.
Monogenic Variants
Previously reported TPO variants were identified in three cases
including two siblings who each harbored a heterozygous
frameshift variant, p.A397Pfs∗76, inherited from a euthyroid
father. An unrelated case was compound heterozygous for
a maternally inherited missense mutation, p.R438H, and a
paternally inherited frameshift variant, p.E17Dfs∗77. All three
cases exhibited severe CH at diagnosis, with significantly elevated
serum TSH values (median, >75 mU/L; range, >75–159 mU/L)
and low fT4 values (median, <4 µg/dL; range, <4–1.02 µg/dL).
Goiter was diagnosed on the neonatal thyroid ultrasound
in cases harboring p.A397Pfs∗76 and during fetal ultrasound
examination in the case with compound heterozygousmutations.
Heterozygous DUOX2 variants were identified in two cases.
One case was heterozygous for DUOX2 p.E1546G, a previously
reported variant that was associated with transient CH. Parental
DNA was unavailable for genotyping. The second case harbored
a novel, maternally inherited variant, DUOX2 p.D1440N,
associated with goiter, mildly elevated blood spot and serum TSH
(14.8 and 21 mU/L, respectively), and normal FT4 1.39 ng/dL.
During the first year, levothyroxine requirements were low (dose
at 1 year of age 1.6 µg/kg), suggesting that the CH may also
eventually resolve.
Two cases harbored heterozygous TSHR variants, both of
which were novel. Variants p.L452P, and p.E107D, were predicted
to be pathogenic by two (p.E107D) or three (p.L452P) algorithms,
and a single carrier parent was identified for each variant
with either symptomatic hypothyroidism (p.L452P) or isolated
hyperthyrotropinemia (p.E107D). Both TSHR variants were
associated with normal thyroid size and mild CH; because
both cases were younger than 3 years, treatment withdrawal
was not possible; however, both individuals readily achieved
normalization of TSH on levothyroxine treatment, unlike some
reported cases (usually with biallelic mutations) in whom TSH
normalization has required supraphysiological FT4 levels (17).
Heterozygous PAX8 mutations were identified in
three cases, two of whom were siblings. All had isolated
hyperthyrotropinemia with a normal-sized GIS. The first case
harbored a frameshift mutation (p.R242Gfs∗37), which is likely
causative, and was inherited from her heterozygous mother who
was also on levothyroxine for hypothyroidism. The missense
variant p.K135R in the siblings was less definitive, and parental
DNA was unfortunately not available for analysis. Although
previously reported in association with CH, it has not been
functionally characterized and is predicted to be tolerated
by SIFT (18). A novel, heterozygous TG variant of uncertain
significance (p.N1365Y) was identified in one further case, which
is unlikely to be causative in isolation because TG variants
associated with CH are usually biallelic.
Oligogenic Variants
Three cases with isolated hyperthyrotropinemia harbored
oligogenic variants, although it is not clear whether all played
a causal role in CH. The first case harbored compound
heterozygous DUOX2 mutations (p.G94S, p.F966Sfs∗29), of
which p.F966Sfs∗29 is a known pathogenic mutation and likely
to be the main cause for CH in this case. Although a coexisting,
heterozygous TSHR variant (p.E506K) was identified, which
was strongly predicted to be pathogenic, it was inherited
from a euthyroid mother. A second case harbored both a
novel, heterozygous TPO mutation (p.E799Q) affecting the
same amino acid as a previously reported mutation (p.E799K)
and a heterozygous TG mutation, resulting in a frameshift
(p.L1791Cfs∗12). Because biallelic TG and TPO mutations are
usually required for CH to develop, the cause for CH has not yet
been completely elucidated in this case. The final case harbored
a known pathogenic, heterozygous TG mutation (p.R296∗) and
a TSHR splice donor variant, c.692 + 1_692 + 4delGTGA. The
latter was unlikely to be a contributor to CH, being inherited
from a euthyroid mother and retaining a canonical 5′ splice
site sequence, making it plausible that normal splicing will be
preserved (Figure 2), and the heterozygosity of the TG mutation
also makes its contribution to CH unclear.
Variant-positive and variant-negative cohorts exhibited
similar thyroid size, biochemistry, and demographic features
(Table 2). Twenty-four-hour urinary iodine concentrations
were assessed in seven mutation-negative cases and three
mutation-positive cases and did not show iodine deficiency
(range, 124–329 µg/L). A single individual with 24-h urinary
iodine concentration of 329 µg/L may have been subject to
excessive iodine intake; however, because this child was younger
than 3 years at the time of sampling, he was too young for
accurate comparison with the WHO school-aged reference
ranges. Anti-TPO titers were assessed in cases with a maternal
history of thyroid disease, either at diagnosis or early in the
follow-up. Fifty-seven percent of the mutation-positive group
and 42% of the mutation-negative group were tested, all of them
showing levels below the measurement level (<10 IU/mL).
DISCUSSION
This is the first study investigating genetic causes of CH in
Macedonian patients. In this small cohort of selected CH cases,
targeted genetic analysis revealed potential pathogenic variants
in TPO, DUOX2, PAX8, TSHR, and TG. Seven variants either
truncated the protein, affecting key functional domains, or had
previously been demonstrated to result in loss of function in vitro.
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FIGURE 2 | Graphic description of the TSHR donor splice site variant in case 33. [] means deleted bases; bold font indicates splice site after deletion.
TABLE 2 | Summary of mutation-positive and mutation-negative cases.
Mutation-positive
cases
Mutation-negative
cases
Number of cases 14 26
Ethnicity of cases 11 Macedonian, 3
Albanian
17 Macedonian, 7
Albanian, 2 Roma
% of cohort 35 65
Familial cases 4 7
Median TSH
(mU/L) and range
26.2 (13.8–159) 35.7 (13.7–152)
% cases with TSH
≥ 50 mU/L
43 31
% with goiter 29 27
% with
normal-sized
gland
71 50
% with hypoplastic
gland
0 23
Genes harboring
variants
TPO (n = 4)
TSHR (n = 4)
DUOX2 (n = 4)
TG (n = 4)
PAX8 (n = 3)
There was no significant difference in median TSH values (Mann–Whitney test p = 0.63)
or proportion of cases with TSH ≥50 mU/L (χ2 test 0.44) or gland morphology (χ2 test,
p = 0.14) between the two groups. Cases with TSH >75 mU/L were said to have TSH
75 mU/L for the purposes of these calculations.
Additionally, nine missense variants were identified in TSHR (n
= 3), TPO (n = 2), DUOX2 (n = 2), PAX8 (n = 1), TG (n
= 1), as well as a donor splice site variant in TSHR. In silico
analyses, genotype–phenotype correlation and analysis of clinical
phenotype were used to assess likelihood of loss of function.
Future studies using functional assays with protein expression in
eukaryotic cells will be essential in order to permitmore definitive
statements regarding pathogenicity, but were outside the scope of
this study.
Macedonian cases harboring TPO mutations all had severe,
goitrous CH, as is typical in this context, and the fetal goiter
observed in one case is a rare, but recognized presentation (19).
Both TPO p.A397Pfs∗76 and p.E17Dfs∗77 have been associated
with CH and iodide organification defect, and pathogenicity
of both mutations has been confirmed in thyroid tissue from
affected patients (20, 21). TPO p.R438H is located within
the TPO heme peroxidase catalytic domain and has been
associated with severe CH, although its effects on catalytic
activity have not been characterized in vitro (22). Congenital
hypothyroidism–associated TPO mutations are usually biallelic;
however, two siblings harbored a TPO mutation, which
was definitively pathogenic (p.A397Pfs∗76) but heterozygous,
without an identifiable mutation on the other allele. Although
heterozygous TPO mutations are occasionally associated with
CH, their heterozygous father was euthyroid; therefore, it is
more likely that they harbor an additional, undetected intronic
or regulatory region mutation on the maternal TPO allele.
In a similar case with total iodide organification defect and
heterozygous TPO mutation, monoallelic TPO expression was
demonstrated in the thyroid gland (23, 24).
Monogenic DUOX2 mutations frequently cause goitrous
transient CH or TSH resistance (15, 25). DUOX2 p.E1546G
exhibits impaired H2O2 synthesis in vitro and has been
associated with permanent CH when inherited in compound
heterozygosity with the non-functional DUOX2 p.M866R (15).
We identified one case who was heterozygous for DUOX2
p.E1546G alone and had non-goitrous, transient CH. Absence of
the highly deleterious DUOX2 p.M866R may have contributed
to this milder phenotype, althoughDUOX2 genotype–phenotype
correlation is poor (26). An additional case had a novel
heterozygous DUOX2 variant p.D1440N affecting a conserved
amino acid within the NADPH-oxidase domain in which
other pathogenic mutations have been identified, for example,
p.G1518S (15, 27, 28). This, together with the associated mild,
goitrous CH, supports pathogenicity of the mutation.
TSHR mutations may underlie CH in cases with normal-
sized or hypoplastic thyroid because TSHR signaling influences
both thyroid growth and hormonogenesis (6). We identified two
heterozygous, monogenic TSHR variants associated with normal
thyroid size and mild CH, which could be consistent with TSHR
dysfunction (p.E107D, p.L452P). Both were novel; however, their
inheritance from parents with isolated hyperthyrotropinemia or
overt hypothyroidism increased the likelihood of pathogenicity.
Conversely, the significance of TSHR p.E506K was unclear
because it did not segregate with phenotype, and TSHR c.692 +
1_692 + 4delGTGA was unlikely to be pathogenic because the
canonical 5′ splice site sequence was preserved.
PAX8 p.R242Gfs∗37 encodes a protein with a preserved paired
domain and octopeptide with a frameshift at the distal end of the
homeodomain homology region and a truncation proximal to the
C-terminal region. Experimentally validated, pathogenic PAX8
mutations usually affect the paired domain, an exception being
PAX8c.989_992 delACCC, which exhibits preserved binding
to a paired domain recognition sequence but transcriptional
inactivity, due to disruption of the C-terminal activation domain
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(29). PAX8 p.R242Gfs∗37 truncates PAX8 one amino acid
downstream of c.989_992 delACCC and thus will be similarly
pathogenic, with the perturbed homeodomain potentially
mediating additional effects. Reported PAX8 mutations are
always heterozygous and can be associated with intrafamilial
phenotype variability ranging from severe CH to euthyroidism
or the isolated hyperthyrotropinemia observed in case 74.
PAX8 p.K135R identified in two siblings is more equivocal.
It is located in the paired domain; although the p.K135A
substitution has been shown to impair wild-type transactivation
function, substitution of lysine (K) for arginine (R), which is
also positively charged, may be better tolerated. There is also one
homozygote for PAX8 p.K135R in the ExAC database, suggesting
its functional consequences are likely to be mild despite its
association with CH in a previous study (8, 30).
Mutation frequency in GIS CH is strongly influenced by
cohort ethnicity and selection criteria, and genetic studies have
not previously been undertaken in Macedonian CH cases.
The rank order of potentially causative genes in our cohort
is comparable with other studies, because TSHR mutations
commonly cause non-autoimune hyperthyrotropinemia, TPO
mutations frequently underlie dyshormonogenesis, and DUOX2
mutations are a common cause of either mild/transient CH or
TSH resistance (6, 25, 28, 31, 32). Surprisingly, although biallelic
TG mutations are a frequent cause of CH, only monoallelic
mutations were identified in our study, which may reflect
the relatively small number of cases screened. Although TG
p.L1791Cfs∗12 and p.R296∗ are pathogenic, both were inherited
in double heterozygosity with the novel TPO variant p.E799Q
and the likely benign TSHR variant c.692+ 1_692+ 4delGTGA,
respectively; therefore, the relative contributions of the two
mutations are not clear, and it is also possible that an undetected,
non-exonic TG mutation on the other allele is contributing to
CH. The significance of TG p.N1365Y in case 51 is equivocal.
No SLC26A7, DUOXA2, NIS, or IYD mutations were
identified. Mutations in the latter three genes are generally
rare; however, because SLC26A7 has not yet been sequenced
in large CH studies, the frequency of CH-associated mutations
is unknown. Larger studies, with an unselected sequencing
approach, are needed to compare genotype–phenotype
correlations in multiethnic Macedonian CH cases and with
CH populations of different ethnicities. There was no significant
difference in thyroid biochemistry or morphology between the
mutation-positive and mutation-negative cases.
Sixty-five percent of our cohort did not harbor a likely
causative mutation, and 79% of our cohort had a normal T4
at diagnosis; therefore, CH was generally mild–moderate. The
incidence of mild GIS CH is increasing, and a previous next-
generation sequencing (NGS) study in such cases found that
biochemically mild CH was less likely to have an identifiable
genetic basis, consistent with our low rate of definitively causal
mutations (33). However, a major limitation to our study is
the fact that we used a phenotype-driven approach, sequentially
screening individual candidate genes, because (as in many
diagnostic settings) an NGS-based panel was not readily available
to us. This approach may have been inadequate for elucidating
the basis of all genetically mediated CH cases.
Next-generation sequencing is now the recommended
approach for evaluating CH, using either a candidate gene panel
or whole-exome (WES) or genome sequencing, and permits
a non–hypothesis-driven approach, additionally detecting
mutations in CH-associated genes associated with an unexpected
phenotype (34, 35). This is important both for GIS CH and
thyroid dysgenesis because variants in genes involved in thyroid
hormone biosynthesis (e.g., Pendrin, TPO, and DUOX2) have
recently been implicated in thyroid dysgenesis, and mutations
in morphogenesis-associated genes (e.g., FOXE1) have been
implicated in GIS CH (18, 34–38). A further advantage of NGS
is the ability to detect oligogenic variants, because cumulative
effects of rare variants in CH-associated genes that confer
minor functional impairment individually have been implicated
in development of both GIS CH and thyroid dysgenesis.
Oligogenicity may also modulate CH phenotype explaining
the variable penetrance and expressivity of genetic defects
observed in familial CH (18, 28, 34, 39, 40). Finally, WES and
whole-genome sequencing have enabled novel genetic causes
of CH to be defined, such as SLC26A7 mutations causing
dyshormonogenesis, and TUBB1 and CDCA8 mutations in
dysgenesis (4, 41, 42).
Our phenotype-driven approach may have missed CH-
associated variants in cases with atypical phenotypes, especially
in cases with transient CH or thyroid hypoplasia where the
sequencing was least comprehensive. Additionally, we did not
sequence NKX2-1, FOXE1, and GLIS3, which also contribute to
isolated GIS CH, although affected patients often have additional
extrathyroidal features (18). Although three digenic cases were
found in our cohort, our Sanger sequencing approach may
also have underestimated the contribution of oligogenicity to
CH in our cases and will only have detected known genetic
causes. Additional limitations include the fact that neonatal
ultrasonography may not always have defined thyroid size
accurately because of technical challenges in scanning babies,
potentially resulting in inappropriate selection of genes for
screening. Moreover, because < 40% of the total number of
Macedonian isolated hyperthyrotropinemia, transient CH, and
thyroid hypoplasia cases were screened, our findings may not be
representative of the entire Macedonian CH population.
Although the true genetic mutation frequency may have
been higher in our cohort had we used an NGS approach,
the low frequency of mutation-positive cases nevertheless
suggests that novel genetic or environmental factors alone,
or in concert with recognized genetic causes, may play
a role in the pathogenesis of GIS CH. Five cases with
goitrous CH (three familial) were not found to have a
causative mutation despite comprehensive screening of all genes
involved in thyroid hormone biosynthesis. Because mutations
in morphogenesis-associated genes have not yet been found
to cause goitrous CH to the best of our knowledge, this
observation supports the existence of alternative causes for
dyshormonogenic goiter. Similar mutation-negative familial or
consanguineous cases have been reported in other studies,
justifying a role for future exome or genome sequencing studies
to investigate the occurrence of mutations in novel genes in
this subset.
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The etiology of transient CH in particular is also poorly
ascertained in the literature with mutations in DUOX2 and
DUOXA2 representing the best characterized genetic causes;
however, only one transient CH case in our study harbored a
DUOX2 mutation, and no DUOXA2 mutations were detected
(28). Environmental contributors to transient CH include
suboptimal iodine status; however, urinary iodine concentration
was unfortunately ascertained in only 10 cases asynchronously
with CH diagnosis. The rationale for this is that Macedonia
is one of the 11 countries in the world that has continuously
sustained iodine sufficiency according to the Iodine Global
Network Reports (2018) (43). Consistent with this, the 10
evaluated cases were iodine-replete at assessment; however, we
cannot definitively exclude an etiological role for neonatal iodide
deficiency or excess, especially in cases with transient CH or
isolated hyperthyrotropinemia. Additionally, the roles of thyroid
disruptors such as perchlorate, thiocyanate, and nitrates in CH
have not yet been evaluated.
In summary, in this first genetic evaluation of CH cases
with GIS or thyroid hypoplasia in Macedonia, direct sequencing
identified definitively causative variants in four cases and
potentially pathogenic variants in a further 10, involving TPO,
TG, TSHR, DUOX2, and PAX8, all genes that are frequently
implicated in CHworldwide. Despitemethodological limitations,
the relatively low mutation frequency suggests that factors
other than recognized monogenic causes (oligogenic variants,
environmental factors, or novel genes) may contribute to GIS CH
in this region, mandating future non–hypothesis-driven, NGS
studies to confirm these findings.
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